Search Results for: CSNK2B

229 interactions involving CSNK2B - casein kinase 2 beta found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
LYN LYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated NF-kB activation
  • Co-stimulation by CD28
  • Co-inhibition by CTLA4
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • CD22 mediated BCR regulation
  • Cyclin D associated events in G1
  • Platelet Adhesion to exposed collagen
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Bosutinib
  • Ponatinib
  • Nintedanib
  • Fostamatinib
LYST lysosomal trafficking regulator
  • Other phagocyte defects, including the following eight diseases: Chediak-Higashi syndrome; Griscelli syndrome, type 1 (GS1); Griscelli syndrome, type 2 (GS2); Griscelli syndrome, type 3 (GS3); beta-actin deficiency; Neutrophil-specific granule deficiency; Myeloperoxidase deficiency; Glucose 6-phosphate dehydrogenase deficiency; Shwachman syndrome
MAPK14 mitogen-activated protein kinase 14
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • CD163 mediating an anti-inflammatory response
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Minocycline
  • Dasatinib
  • 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
  • N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • Doramapimod
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • R-1487
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • SD-0006
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
  • Fostamatinib
MBD4 methyl-CpG binding domain 4, DNA glycosylase
  • Recognition and association of DNA glycosylase with site containing an affected pyrimidine
  • Cleavage of the damaged pyrimidine
  • Displacement of DNA glycosylase by APEX1
MDM2 MDM2 proto-oncogene
  • AKT phosphorylates targets in the cytosol
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • Trafficking of AMPA receptors
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ub-specific processing proteases
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Signaling by ALK fusions and activated point mutants
  • Degradation of CDH1
  • NPAS4 regulates expression of target genes
  • Zinc
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Penile cancer
  • Alveolar rhabdomyosarcoma
  • Choriocarcinoma
  • Osteosarcoma
  • Glioma
MME membrane metalloendopeptidase
  • Metabolism of Angiotensinogen to Angiotensins
  • Physiological factors
  • Neutrophil degranulation
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Candoxatril
  • Omapatrilat
  • N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]Alanine
  • Phosphoramidon
  • N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine
  • [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
  • Daglutril
  • 2-[(1S)-1-BENZYL-2-SULFANYLETHYL]-1H-IMIDAZO[4,5-C]PYRIDIN-5-IUM
  • Thiorphan
  • Sacubitril
  • Candoxatrilat
MOXD1 monooxygenase DBH like 1
MPP2 MAGUK p55 scaffold protein 2
NAP1L1 nucleosome assembly protein 1 like 1
NCF1 neutrophil cytosolic factor 1
  • ROS and RNS production in phagocytes
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Detoxification of Reactive Oxygen Species
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate NADPH Oxidases
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RAC3 GTPase cycle
  • Dextromethorphan
  • Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
NGDN neuroguidin
NMT2 N-myristoyltransferase 2
  • Membrane binding and targetting of GAG proteins
  • eNOS activation
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Myristoyl-Coa
  • S-(2-oxo)pentadecylcoa
  • 1-(CYCLOHEXYLAMINO)-3-(6-METHYL-3,4-DIHYDRO-1H-CARBAZOL-9(2H)-YL)PROPAN-2-OL
  • (Z)-3-BENZYL-5-(2-HYDROXY-3-NITROBENZYLIDENE)-2-THIOXOTHIAZOLIDIN-4-ONE
NOLC1 nucleolar and coiled-body phosphoprotein 1
  • Doxorubicin
NOTCH3 notch receptor 3
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Processing in Golgi
  • Notch-HLH transcription pathway
  • Defective LFNG causes SCDO3
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • Noncanonical activation of NOTCH3
  • Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL)
NPAS2 neuronal PAS domain protein 2
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • PPARA activates gene expression
  • Heme signaling
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes
  • The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex
NRBP1 nuclear receptor binding protein 1
  • Nuclear Receptor transcription pathway
NRF1 nuclear respiratory factor 1
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Transcriptional activation of mitochondrial biogenesis
  • Mitochondrial unfolded protein response (UPRmt)
NTAQ1 N-terminal glutamine amidase 1
ODC1 ornithine decarboxylase 1
  • Regulation of ornithine decarboxylase (ODC)
  • Metabolism of polyamines
  • Pyridoxal phosphate
  • Spermine
  • Sildenafil
  • Valproic acid
  • Putrescine
  • Pyridoxine phosphate
  • N-Pyridoxyl-Glycine-5-Monophosphate
  • L-Eflornithine
  • N(6)-(pyridoxal phosphate)-L-lysine
  • Geneticin
  • Eflornithine
OGA O-GlcNAcase
  • Streptozocin

Page 7 out of 12 pages